Reflector is Pharm Exec Europe's man inside the EU.
Politicians and health campaigners are celebrating the final agreement of the EU's new clinical trials rules. But the European drug industry is not so euphoric, writes Reflector.
The plan to accelerate generic pricing and reimbursement has become another tragic European casualty.
Roche and Novartis have been fined in Italy on pricing conspiracy charges, fueling a wider debate in Europe about expenditure, efficiency and off-label prescribing.
Reflector looks at the growing pains of the European Medicine Agency (EMA) as it faces the key policy challenges of 2014.
Reflector looks at the growing pains of the European Medicine Agency (EMA) as it faces key policy challenges of 2014.
European efforts to crack down on safety and pricing issues in the marketing of medical devices may portend long-term problems for Big Pharma.
By the start of 2014, industry expects to have a clearer idea of how far the US-EU free trade pact is going.
The ?70 billion budget is still subject to final agreement on the European Union's overall spending plans for 2014-2020.
The European Union's attempt to update its transparency rules sparks new debate.
Supply Chain Strategy: Managing risk and opportunity in a changing global landscape
Sponsored By PricewaterhouseCoopers LLP Optimizing the Multi-Sponsor REMS Experience (Risk Evaluation & Mitigation Strategies)
Sponsored By PricewaterhouseCoopers LLP Effective Resource Planning: Reducing Clinical Project Risk and Operating Cost
Sponsored By ClearTrial